glycerophosphoethanolamine has been researched along with Acute Confusional Senile Dementia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL | 1 |
| Blusztajn, JK; Growdon, JH; Logue, M; Lopez Gonzalez-Coviella, I; Wurtman, RJ | 1 |
2 other study(ies) available for glycerophosphoethanolamine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Biological Availability; Caproates; Diglycerides; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Phosphatidylethanolamines; Plasmalogens; Rabbits; Tissue Distribution | 2011 |
Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.
Topics: Aged; Alzheimer Disease; Brain; Down Syndrome; Female; Glycerylphosphorylcholine; Humans; Male; Middle Aged; Nerve Degeneration; Phosphatidylethanolamines | 1990 |